<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7450</journal-id>
<journal-title><![CDATA[Revista Colombiana de Psiquiatría]]></journal-title>
<abbrev-journal-title><![CDATA[rev.colomb.psiquiatr.]]></abbrev-journal-title>
<issn>0034-7450</issn>
<publisher>
<publisher-name><![CDATA[Asociacion Colombiana de Psiquiatria.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-74502024000400584</article-id>
<article-id pub-id-type="doi">10.1016/j.rcp.2022.10.007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Consenso colombiano del tratamiento con cannabidiol (CBD) puro en psiquiatría]]></article-title>
<article-title xml:lang="en"><![CDATA[Colombian Consensus of Treatment with Pure Cannabidiol (CBD) in Psychiatry]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cassiani-Miranda]]></surname>
<given-names><![CDATA[Carlos A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arango-Dávila]]></surname>
<given-names><![CDATA[César A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Giraldo]]></surname>
<given-names><![CDATA[Jeffrey]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Parra-Vera]]></surname>
<given-names><![CDATA[Mario D.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tellez-Vargas]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales-Puerto]]></surname>
<given-names><![CDATA[Lilian Rocío]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Santander Facultad de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[Bucaramanga ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Icesi  ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad del Rosario  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Vitale servicios médicos especializados  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidad del Bosque  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Instituto Colombiano del Sistema Nervioso  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<volume>53</volume>
<numero>4</numero>
<fpage>584</fpage>
<lpage>597</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0034-74502024000400584&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0034-74502024000400584&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0034-74502024000400584&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  El trastorno del espectro autista, el trastorno depresivo mayor, los trastornos de ansiedad, el trastorno de estrés postraumático, la esquizofrenia, el insomnio y los trastornos relacionados con sustancias psicotrópicas son enfermedades frecuentes a nivel mundial y en Colombia. Los tratamientos farmacológicos disponibles para el manejo de trastornos mentales (TM) son eficaces, aunque en ocasiones las reacciones adversas limitan su uso. Adicionalmente, algunos pacientes no tienen una respuesta adecuada, lo que genera la necesidad de investigar nuevos fármacos, eficaces y seguros.  Metodología:  Se desarrolló un consenso Delphi en tiempo real, con un panel de siete especialistas en psiquiatría y un grupo de epidemiólogos desarrolladores. Se realizó una búsqueda sistemática en tres bases de datos especializadas y en artículos aportados por el panel de expertos participantes en el consenso. Se aplicaron dos cuestionarios al grupo de expertos, quienes los respondieron en forma anónima y en una plataforma en línea, con la escala de Likert.  Resultados:  Se establecieron recomendaciones a partir de la evidencia disponible y de la experiencia de los expertos.  Conclusiones:  Existe plausibilidad biológica en estudios clínicos y preclínicos que sugieren la efectividad de cannabidiol (CBD) puro de grado farmacéutico como terapia coadyuvante, para el control de síntomas asociados a algunos TM, como esquizofrenia y trastornos relacionados con el abuso de sustancias psicotrópicas. Sin embargo, se requieren ensayos clínicos más rigurosos para formular recomendaciones más precisas sobre el CBD en el tratamiento de otros TM. Además, se considera que el CBD puro de grado farmacéutico es un tratamiento seguro.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Autism spectrum disorder, major depressive disorder, anxiety disorders, post-traumatic stress disorder, schizophrenia, insomnia, and disorders related to psychotropic substances are common diseases worldwide and in Colombia. The pharmacological treatments available for the management of mental disorders are effective, although adverse reactions sometimes limit their use, additionally, some patients do not have an adequate response to them, which generates the need to develop new effective and safe drugs.  Methodology:  A Delphi consensus was developed in real time, with a panel of seven psychiatric specialists and a group of developer epidemiologists, a systematic search was carried out in three specialized databases and in contributed articles. By the panel of experts participating in the consensus, two questionnaires were applied for consideration by the group of experts, anonymously and on an online platform with the Likert scale.  Results:  Recommendations were established based on the available evidence and the experience provided by the experts.  Conclusions:  There is biological plausibility in clinical and preclinical studies that suggest the effectiveness of the use of pure pharmaceutical-grade CBD, as adjunctive therapy, for the control of symptoms associated with mental disorders such as schizophrenia and disorders related to the abuse of psychotropic substances. However, more rigorous clinical trials are required to make more precise recommendations on CBD in the treatment of other mental disorders. Additionally, pure pharmaceutical-grade CBD is considered a safe treatment.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cannabidiol]]></kwd>
<kwd lng="es"><![CDATA[Consenso]]></kwd>
<kwd lng="es"><![CDATA[Esquizofrenia]]></kwd>
<kwd lng="es"><![CDATA[Trastornos relacionados con sustancias]]></kwd>
<kwd lng="en"><![CDATA[Cannabidiol]]></kwd>
<kwd lng="en"><![CDATA[Consensus]]></kwd>
<kwd lng="en"><![CDATA[Schizophrenia]]></kwd>
<kwd lng="en"><![CDATA[Substance-related disorders]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Plan de acción sobre salud mental 2013-2020]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blessing]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Steenkamp]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Manzanares]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Marmar]]></surname>
<given-names><![CDATA[CR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol as a potential treatment for anxiety disorders]]></article-title>
<source><![CDATA[Neurotherapeutics]]></source>
<year>2015</year>
<volume>12</volume>
<page-range>825-36</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>2017 DALYs GBD</collab>
<article-title xml:lang=""><![CDATA[Collaborators HALE. Global regional national disability-adjusted life-years (DALYs) for 359 diseases injuries healthy life expectancy (HALE) for 195 countries territories 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017]]></article-title>
<source><![CDATA[Lancet Lond Engl]]></source>
<year>2018</year>
<volume>392</volume>
<numero>10159</numero>
<issue>10159</issue>
<page-range>1859-922</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rehm]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shield]]></surname>
<given-names><![CDATA[KD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global burden of disease and the impact of mental and addictive disorders]]></article-title>
<source><![CDATA[Curr Psychiatry Rep]]></source>
<year>2019</year>
<volume>21</volume>
<page-range>10</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castaüo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Salud mental en Colombia]]></article-title>
<source><![CDATA[Un análisis crítico. Ces Med]]></source>
<year>2018</year>
<volume>32</volume>
<page-range>129-40</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dakic]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mental health burden and unmet needs for treatment: a call for justice]]></article-title>
<source><![CDATA[Br J Psychiatry J Ment Sci]]></source>
<year>2020</year>
<volume>216</volume>
<page-range>241-2</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ibarra-Lecue]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Pilar-Cuéllar]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Muguruza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Florensa-Zanuy]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Urigüen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The endocannabinoid system in mental disorders: Evidence from human brain studies]]></article-title>
<source><![CDATA[Biochem Pharmacol]]></source>
<year>2018</year>
<volume>157</volume>
<page-range>97-107</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mandolini]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Lazzaretti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pigoni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Oldani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Delvecchio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brambilla]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview]]></article-title>
<source><![CDATA[Epidemiol Psychiatr Sci]]></source>
<year>2018</year>
<volume>27</volume>
<page-range>327-35</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leweke]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Lange]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Fritze]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Topor]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Koethe]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of the endocannabinoid system in the pathophysiology of schizophrenia: Implications for pharmacological intervention]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2018</year>
<volume>32</volume>
<page-range>605-19</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howlett]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Breivogel]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Childers]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Deadwyler]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Hampson]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Porrino]]></surname>
<given-names><![CDATA[LJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabinoid physiology and pharmacology: 30 years of progress]]></article-title>
<source><![CDATA[Neuropharmacology]]></source>
<year>2004</year>
<volume>47</volume>
<page-range>345-58</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karniol]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
<name>
<surname><![CDATA[Shirakawa]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kasinski]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeferman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carlini]]></surname>
<given-names><![CDATA[EA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol interferes with the effects of A9-tetrahydrocannabinol in man]]></article-title>
<source><![CDATA[Eur J Pharmacol]]></source>
<year>1974</year>
<volume>28</volume>
<page-range>172-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crippa]]></surname>
<given-names><![CDATA[JAS]]></given-names>
</name>
<name>
<surname><![CDATA[Derenusson]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Wichert-Ana]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Duran]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Martin-Santos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuralbasis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report]]></article-title>
<source><![CDATA[J Psychopharmacol (Oxf)]]></source>
<year>2011</year>
<volume>25</volume>
<page-range>121-30</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuardi]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Shirakawa]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Finkelfarb]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Karniol]]></surname>
<given-names><![CDATA[IG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Action of cannabidiol on the anxiety and other effects produced by 9-THC in normal subjects]]></article-title>
<source><![CDATA[Psychopharmacology (Berl)]]></source>
<year>1982</year>
<volume>76</volume>
<page-range>245-50</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuardi]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Cosme]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Graeff]]></surname>
<given-names><![CDATA[FG]]></given-names>
</name>
<name>
<surname><![CDATA[Guimarães]]></surname>
<given-names><![CDATA[FS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of ipsapirone and cannabidiol on human experimental anxiety]]></article-title>
<source><![CDATA[J Psychopharmacol (Oxf)]]></source>
<year>1993</year>
<volume>7</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>82-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zuardi]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Teixeira]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Karniol]]></surname>
<given-names><![CDATA[IC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological interaction of the effects of delta 9-transtetrahydrocannabinol and cannabidiol on serum corticosterone levels]]></article-title>
<source><![CDATA[in rats Arch Int Pharmacodyn Ther]]></source>
<year>1984</year>
<volume>269</volume>
<page-range>12-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cannabis and Cannabinoids: Pharmacology, toxicology and therapeutic potential]]></source>
<year>2013</year>
<edition>1</edition>
<publisher-name><![CDATA[Taylor &amp; Francis group]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monti]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypnoticlike effects of cannabidiol in the rat]]></article-title>
<source><![CDATA[Psychopharmacology (Berl)]]></source>
<year>1977</year>
<volume>55</volume>
<page-range>263-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crippa]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Guimarães]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Campos]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Zuardi]]></surname>
<given-names><![CDATA[AW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a New Age]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2018</year>
<volume>9</volume>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zlebnik]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Cheer]]></surname>
<given-names><![CDATA[JF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beyond the CB1 Receptor: Is cannabidiol the answer for disorders of motivation?]]></article-title>
<source><![CDATA[Annu Rev Neurosci]]></source>
<year>2016</year>
<volume>8</volume>
<page-range>1-17</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<collab>World Health Organization Expert</collab>
<source><![CDATA[Committee on Drug Dependence Thirty-ninth Meeting]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[CANNABIDIOL (CBD)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud y de la Protección Social</collab>
<source><![CDATA[Instituto Nacional de Vigilancia de Medicamentos y Alimentos]]></source>
<year></year>
<publisher-name><![CDATA[Neviot]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boulkedid]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Abdoul]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Loustau]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sibony]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Alberti]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review]]></article-title>
<source><![CDATA[PloS One]]></source>
<year>2011</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodman]]></surname>
<given-names><![CDATA[LA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Snowball Sampling]]></article-title>
<source><![CDATA[Ann Math Stat]]></source>
<year>1961</year>
<volume>32</volume>
<page-range>148-70</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Matas]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diseñío del formato de escalas tipo Likert: un estado de la cuestión]]></article-title>
<source><![CDATA[Rev Electrónica Investig Educ]]></source>
<year>2018</year>
<volume>20</volume>
<page-range>38-47</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brook]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Chassin]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Fink]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Kosecoff]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[RE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A method for the detailed assessment of the appropriateness of medical technologies]]></article-title>
<source><![CDATA[Int J Technol Assess Health Care]]></source>
<year>1986</year>
<volume>2</volume>
<page-range>53-63</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Titus]]></surname>
<given-names><![CDATA[SL.]]></given-names>
</name>
</person-group>
<collab>Evaluating U. S.</collab>
<article-title xml:lang=""><![CDATA[medical schools' efforts to educate faculty researchers on research integrity and research misconduct policies and procedures]]></article-title>
<source><![CDATA[Account Res]]></source>
<year>2014</year>
<volume>21</volume>
<page-range>9-25</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hurd]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
<name>
<surname><![CDATA[Spriggs]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alishayev]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Winkel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gurgov]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kudrich]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>2019</year>
<volume>176</volume>
<page-range>911-22</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[CJA]]></given-names>
</name>
<name>
<surname><![CDATA[Das]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Joye]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Curran]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Kamboj]]></surname>
<given-names><![CDATA[SK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings]]></article-title>
<source><![CDATA[Addict Behav]]></source>
<year>2013</year>
<volume>38</volume>
<page-range>2433-6</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Schafer]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Curran]]></surname>
<given-names><![CDATA[HV.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol attenuates the appetitive effects of (9-Tetrahydrocannabinol in humans smoking their chosen cannabis]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>2010</year>
<volume>35</volume>
<page-range>1879-85</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="">
<collab>FDA</collab>
<source><![CDATA[iolex: información de prescripción]]></source>
<year>2018</year>
<numero>4282447</numero>
<issue>4282447</issue>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGuire]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Robson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cubala]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vasile]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Morrison]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Barron]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>2018</year>
<volume>175</volume>
<page-range>225-31</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonaccorso]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ricciardi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zangani]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chiappini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schifano]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol (CBD) use in psychiatric disorders: A systematic review]]></article-title>
<source><![CDATA[NeuroToxicology]]></source>
<year>2019</year>
<volume>74</volume>
<page-range>282-98</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Linares]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Zuardi]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Queiroz]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Mechoulam]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Guimarães]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test]]></article-title>
<source><![CDATA[Braz J Psiquiatry]]></source>
<year>2019</year>
<volume>41</volume>
<page-range>9-14</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sales]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fogaca]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Sartim]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[VS]]></given-names>
</name>
<name>
<surname><![CDATA[Wegener]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Guimarães]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol induces rapid and sustained antidepressant-like effects through increased BDNF signaling and synaptogenesis in the prefrontal cortex]]></article-title>
<source><![CDATA[Mol Neurobiol]]></source>
<year>2019</year>
<volume>56</volume>
<page-range>1070-81</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solowij]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Broyd]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Greenwood]]></surname>
<given-names><![CDATA[L-M]]></given-names>
</name>
<name>
<surname><![CDATA[van Hell]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Martelozzo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rueb]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomised controlled trial of vaporised &#916;9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects]]></article-title>
<source><![CDATA[Eur Arch Psychiatry Clin Neurosci]]></source>
<year>2019</year>
<volume>269</volume>
<page-range>17-35</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prud'homme]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cata]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jutras-Aswad]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol as an intervention for addictive behaviors: A systematic review of the evidence]]></article-title>
<source><![CDATA[Subst Abuse]]></source>
<year>2015</year>
<volume>9</volume>
<page-range>33-8</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Chisholm]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Parikh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Charlson]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Degenhardt]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dua]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global priorities for addressing the burden of mental, neurological and substance Use disorders]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Chisholm]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dua]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Laxminarayan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Medina-Mora]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<source><![CDATA[Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, (Volume 4) [Internet]]]></source>
<year>2016</year>
<edition>Third</edition>
<publisher-loc><![CDATA[Washington (DC) ]]></publisher-loc>
<publisher-name><![CDATA[The International Bank for Reconstruction and Development/The World Bank]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hennemann]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Farnsteiner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sander]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Internet- and mobile-based aftercare and relapse prevention in mental disorders: A systematic review and recommendations for future research]]></article-title>
<source><![CDATA[Internet Interv]]></source>
<year>2018</year>
<volume>14</volume>
<page-range>1-17</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association between medication adherence and disease stability in patients with severe mental disorders and area variation: community-based prospective study in southwest China]]></article-title>
<source><![CDATA[Community Ment Health J]]></source>
<year>2020</year>
<volume>56</volume>
<page-range>322-7</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edgcomb]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Zima]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medication adherence among children and adolescents with severe mental illness: A systematic review and meta-analysis]]></article-title>
<source><![CDATA[J Child Adolesc Psychopharmacol]]></source>
<year>2018</year>
<volume>28</volume>
<page-range>508-20</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartung]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Low]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jindai]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mansoor]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Judge]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mendelson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interventions to improve pharmacological adherence among adults with psychotic spectrum disorders and bipolar disorder: A systematic review]]></article-title>
<source><![CDATA[Psychosomatics]]></source>
<year>2017</year>
<volume>58</volume>
<page-range>101-12</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Saavedra]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Testing the hypothesis of subtypes of nonadherence in schizophrenia and schizoaffective disorder: A prospective study]]></article-title>
<source><![CDATA[World J Psychiatry]]></source>
<year>2020</year>
<volume>10</volume>
<page-range>260-71</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lieberman]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Stroup]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[McEvoy]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Swartz]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenheck]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Perkins]]></surname>
<given-names><![CDATA[DO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of antipsychotic drugs in patients with chronic schizophrenia]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2005</year>
<volume>353</volume>
<page-range>1209-23</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mancevski]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rosoklija]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kurzon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Serafimova]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ortakov]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Trencevska]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of introduction of neuroleptics on symptomatology in chronic schizophrenia inpatients]]></article-title>
<source><![CDATA[Schizophrenia Bull]]></source>
<year>2005</year>
<volume>31</volume>
<page-range>495-6</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nolen]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Luckenbaugh]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Altshuler]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Suppes]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[McElroy]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Frye]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlates of 1-year prospective outcome in bipolar disorder: Results from the Stanley foundation bipolar network]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>2004</year>
<volume>161</volume>
<page-range>1447-54</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maletic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Oakes]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Iyengar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ball]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurobiology of depression: an integrated view of key findings: Neurobiology of depression]]></article-title>
<source><![CDATA[Int J Clin Pract]]></source>
<year>2007</year>
<volume>61</volume>
<page-range>2030-40</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roy-Byrne]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment-refractory anxiety; definition, risk factors, and treatment challenges]]></article-title>
<source><![CDATA[Dialogues Clin Neurosci]]></source>
<year>2015</year>
<volume>17</volume>
<page-range>191-206</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Tran]]></surname>
<given-names><![CDATA[DX.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors associated with substance use disorder treatment completion: a cross-sectional analysis of justice-involved adolescents]]></article-title>
<source><![CDATA[Subst Abuse Treat Prev Policy]]></source>
<year>2020</year>
<volume>15</volume>
<page-range>92</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haughwout]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Harford]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Castle]]></surname>
<given-names><![CDATA[IJP]]></given-names>
</name>
<name>
<surname><![CDATA[Grant]]></surname>
<given-names><![CDATA[BF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment utilization among adolescent substance users: findings from the 2002 to 2013 National Survey on Drug Use and Health]]></article-title>
<source><![CDATA[Alcohol Clin Exp Res]]></source>
<year>2016</year>
<volume>40</volume>
<page-range>1717-27</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaudiano]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Wenze]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Weinstock]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Tezanos]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[IW.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valued living and its relationship to medication adherence in patients with bipolar and comorbid substance use disorders]]></article-title>
<source><![CDATA[J Nerv Ment Dis]]></source>
<year>2017</year>
<volume>205</volume>
<page-range>178-81</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Appiah]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term relapse prevention strategies among poly-substance users in Ghana: New insights for clinical practice]]></article-title>
<source><![CDATA[J Ethn Subst Abuse]]></source>
<year>2022</year>
<volume>21</volume>
<page-range>1104-19</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Stockings]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tran]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
<name>
<surname><![CDATA[Zagic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Lancet Psychiatry]]></source>
<year>2019</year>
<volume>6</volume>
<page-range>995-1010</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGuire]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Robson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cubala]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vasile]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Morrison]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Barron]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial]]></article-title>
<source><![CDATA[Am J Psychiatry]]></source>
<year>2018</year>
<volume>175</volume>
<page-range>225-31</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leweke]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Piomelli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pahlisch]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Muhl]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gerth]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Hoyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia]]></article-title>
<source><![CDATA[Transl Psychiatry]]></source>
<year>2012</year>
<volume>2</volume>
</nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergamaschi]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Queiroz]]></surname>
<given-names><![CDATA[RHC]]></given-names>
</name>
<name>
<surname><![CDATA[Chagas]]></surname>
<given-names><![CDATA[MHN]]></given-names>
</name>
<name>
<surname><![CDATA[de Oliveira]]></surname>
<given-names><![CDATA[DCG]]></given-names>
</name>
<name>
<surname><![CDATA[De Martinis]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Kapczinski]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>2011</year>
<volume>36</volume>
<page-range>1219-26</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Linares]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Zuardi]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Queiroz]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Mechoulam]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Guimarães]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test]]></article-title>
<source><![CDATA[Braz JPsychiatry]]></source>
<year>2019</year>
<volume>41</volume>
<page-range>9-14</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schlag]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Baldwin]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Barnes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bazire]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Coathup]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Curran]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medical cannabis in the UK: From principle to practice]]></article-title>
<source><![CDATA[J Psychopharmacol]]></source>
<year>2020</year>
<volume>34</volume>
<page-range>931-7</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chesney]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Oliver]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sovi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Englund]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse effects of cannabidiol: a systematic review and meta-analysis ofrandomized clinicaltrials]]></article-title>
<source><![CDATA[Neuropsychopharmacology]]></source>
<year>2020</year>
<volume>45</volume>
<page-range>1799-806</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hádener]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gelmi]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Martin-Fabritius]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Weinmann]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Pfáffli]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cannabinoid concentrations in confiscated cannabis samples and in whole blood and urine after smoking CBD-rich cannabis as a tobacco substitute]]></article-title>
<source><![CDATA[Int J Legal Med]]></source>
<year>2019</year>
<volume>133</volume>
<page-range>821-32</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spindle]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Cone]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kuntz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Bigelow]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Flegel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Urinary pharmacokinetic profile of cannabinoids following administration of vaporized and oral Cannabidiol and vaporized CBD-dominant Cannabis]]></article-title>
<source><![CDATA[J Anal Toxicol]]></source>
<year>2020</year>
<volume>44</volume>
<page-range>109-25</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adulterants in Urine Drug Testing]]></article-title>
<source><![CDATA[Advances in clinical chemistry]]></source>
<year>2016</year>
<page-range>123-63</page-range><publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Wilkinson]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Kapur]]></surname>
<given-names><![CDATA[BM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validation of self-reported cannabis use by urine analysis]]></article-title>
<source><![CDATA[Addict Behav]]></source>
<year>1988</year>
<volume>13</volume>
<page-range>147-50</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devinsky]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Cross]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Laux]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Marsh]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Nabbout]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trial of Cannabidiol for drug-resistant seizures in the Dravet syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>376</volume>
<page-range>2011-20</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Devinsky]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Cross]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Villanueva]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Wirrell]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Privitera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>378</volume>
<page-range>1888-97</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
